Skip to content
Alligator Bioscience

Alligator Bioscience

sv
  • About Alligator
    • Board of directors
    • Management
    • Collaborations and partnerships
    • Career
  • Research & development
    • Immunotherapy of cancer
    • Pipeline
      • Mitazalimab
      • ATOR-1017
      • ALG.APV-527
      • Research projects
    • Scientific publications
    • Technology platform
      • ALLIGATOR-FAB™
      • ALLIGATOR-GOLD®
      • FIND®
    • Scientific advisors
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and shareholders
    • Analysts
    • Preferential rights issue 2021
    • IPO
    • Financial reports
      • Annual reports
      • Interim reports
    • Calendar
    • Presentations
    • Subscribe
  • News
    • Press releases
    • Subscribe
  • Contact
  • SV

  • Tumor-directed immunotherapy of cancer

Latest News

  • 22 Sep 2021 – Alligator to Participate in Upcoming Investor Conferences
  • 2 Sep 2021 – Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipeline
  • 2 Sep 2021 – Positive Results from the Scandion Oncology and Alligator Bioscience Collaboration Further Supports Efficacy of Mitazalimab in Combination Therapy
  • 18 Aug 2021 – Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion Corporation
More news

Calendar

  • 21 Oct 2021 ‐ Interim Report July-September 2021
  • 11 Feb 2022 ‐ Interim Report October-December 2021
  • 27 Apr 2022 ‐ Interim Report January-March 2022
  • 5 May 2022 ‐ Annual General Meeting 2022

Alligator Bioscience Q2 report

Listen to the Webcast here

 

About

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies.

Links

  • About Alligator
  • Research and development
  • Corporate governance
  • Investors
  • News
  • Contact
  • Privacy policy

Contact

Alligator Bioscience AB
Medicon Village
Scheelevägen 2
SE-223 81 Lund
Sweden

Phone: + 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com

Subscribe

Subscribe to get our pressreleases by email.

SUBSCRIBE

Alligator Bioscience

© Copyright 2018 - Alligator Bioscience AB